Retinal angiomatous proliferation in age-related macular degeneration. Review of retinal angiomatous proliferation or type 3 neovascularization. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Gass JD. Stereoscopic Atlas of Macular Diseases. St Louis, MO: Mosby; Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol. Vascular endothelial growth factor upregulation in human central retinal vein occlusion.
Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye Lond.
J Neurotrauma. Drusen complement components C3a and C5a promote choroidal neovascularization. Relationship between RPE and choriocapillaris in age-related macular degeneration. Holmes DI, Zachary I. The vascular endothelial growth factor VEGF family: angiogenic factors in health and disease. Genome Biol. Iyer S, Acharya KR. Tying the knot: the cystine signature and molecular-recognition processes of the vascular endothelial growth factor family of angiogenic cytokines. FEBS J. Vascular endothelial growth factor VEGF and its receptors. Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p Hum Genet.
The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. The biology of VEGF and its receptors. Lymphatic endothelium: a new frontier of metastasis research. Nat Cell Biol. VEGF receptor signalling — in control of vascular function. Nat Rev Mol Cell Biol. Djordjevic S, Driscoll PC. Targeting VEGF signalling via the neuropilin co-receptor. Drug Discov Today. The role of VEGF receptors in angiogenesis; complex partnerships.
Cell Mol Life Sci. Biochem Biophys Res Commun. Drugs R D.
Cytokine traps: multi-component, high-affinity blockers of cytokine action. Stewart MW. What are the half-lives of ranibizumab and aflibercept VEGF trap-eye in human eyes? Calculations with a mathematical model. Eye Rep. Pharmacokinetics of intravitreal ranibizumab Lucentis. Pharmacokinetics of intravitreal bevacizumab Avastin.
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Vol II. Stuggart, Germany: Schattauer-Verlag; Permeability of ocular vessels and transport across the blood-retinal-barrier. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Intravitreal aflibercept VEGF trap-eye in wet age-related macular degeneration. Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates.
A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after week fixed dosing. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration.
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
About this book
Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Non-responders to bevacizumab Avastin therapy of choroidal neovascular lesions. Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Initial non-responders to ranibizumab in the treatment of age-related macular degeneration AMD. Clin Ophthalmol. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration.
Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
Initial utilization of aflibercept in exudative age-related macular degeneration. Eur J Ophthalmol. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.
Risk Factors for Age-related Macular Degeneration | touchOPHTHALMOLOGY
Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int. J Ophthalmol. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab.
Register for a free account
Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: month results. Schachat AP. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Idiopathic polypoidal choroidal vasculopathy IPCV. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Polypoidal choroidal vasculopathy in elderly Chinese patients. Graefes Arch Clin Exp Ophthalmol.
- Tools of Radio Astronomy;
- Red Thunder.
- Conjunctival lymphoma during pregnancy: a case report | BMC Ophthalmology | Full Text;
- Article tools;
- Open verification methodology cookbook.
Related Opthalmic Pathol., Intraoc. Tumors [2008-9 ]
Copyright 2019 - All Right Reserved